DeepMed Research

MILLENNIUM PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1993-01-01

Employees: 1K

Market Cap: -

Website: http://www.takedaoncology.com

Clinical Trials

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: TAK-593

First Posted Date: 2008-10-16

Last Posted Date: 2010-04-27

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT00773929

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 3

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Rituximab 375 mg/m^2
Drug: Cyclophosphamide 750 mg/m^2
Drug: Doxorubicin 50 mg/m^2
Drug: VELCADE 1.3 mg/m^2
Drug: Prednisone 100 mg/m^2
Drug: Vincristine 1.4 mg/m^2

First Posted Date: 2008-07-25

Last Posted Date: 2018-07-12

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 487

Registration Number: NCT00722137

Locations: 🇿🇦
Chris Hani Baragwanath Hospital, Johannesburg, Gauteng, South Africa
🇿🇦
Medical Oncology Center of Rosebank, Johannesburg, Gauteng, South Africa
🇿🇦
University of the Witwatersrand Oncology, Johannesburg, Gauteng, South Africa

and more 147 locations

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: VELCADE Administered by subcutaneous injection
Drug: VELCADE Administered by intravenous infusion

First Posted Date: 2008-07-25

Last Posted Date: 2011-10-10

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 222

Registration Number: NCT00722566

Locations: 🇧🇪
UZ Brussel Department Medical Oncology Laarbeeklaan 101, Brussel, Belgium
🇩🇪
Universitätsklinikum Münster Onkologische Ambulanz West Albert-Schweitzer-Str. 33, Münster, Germany
🇫🇷
Hôtel DIEU, Service D'Hématologie Place Alexis RICORDEAU, NANTES Cedex 01, France

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma
Lymphoma
Hematologic Malignancies
Hodgkin Lymphoma

Interventions: Drug: MLN4924

First Posted Date: 2008-07-25

Last Posted Date: 2013-11-18

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 56

Registration Number: NCT00722488

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Phase 2

Completed

Conditions: Relapsed Follicular Lymphoma

Interventions: Drug: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: VELCADE
Drug: prednisone

First Posted Date: 2008-07-15

Last Posted Date: 2013-04-29

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 55

Registration Number: NCT00715208

Locations: 🇺🇸
Loma Linda U Cancer Center, Loma Linda, California, United States
🇺🇸
Oklahoma Oncology and Hematology, PC, Tulsa, Oklahoma, United States
🇺🇸
Desert Hematology Medical Group, Inc., Rancho Mirage, California, United States

and more 39 locations

Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease

Phase 2

Completed

Conditions: Atherosclerosis

Interventions: Drug: MLN1202
Other: Placebo

First Posted Date: 2008-07-15

Last Posted Date: 2008-07-15

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 108

Registration Number: NCT00715169

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Phase 1

Completed

Conditions: B-cell Follicular Lymphoma
B-cell Marginal Zone Lymphoma
Diffuse Large B-cell Lymphoma
B-cell Mantle Cell Lymphoma
B-cell Small Lymphocytic Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Multiple Myeloma
Waldenstrom's Macroglobulinemia
Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified
Angioimmunoblastic T-cell Lymphoma

Interventions: Drug: Alisertib

First Posted Date: 2008-06-13

Last Posted Date: 2019-05-31

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 58

Registration Number: NCT00697346

Study of MLN4924 in Adult Patients With Nonhematologic Malignancies

Phase 1

Completed

Conditions: Advanced Nonhematologic Malignancies

Interventions: Drug: MLN4924

First Posted Date: 2008-05-14

Last Posted Date: 2013-07-16

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 62

Registration Number: NCT00677170

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Institute for Drug Development, San Antonio, Texas, United States
🇺🇸
Cancer Therapy & Research Center at the UT Health Science Center, San Antonio, Texas, United States

Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: LDP-02
Drug: Placebo

First Posted Date: 2008-04-09

Last Posted Date: 2008-04-09

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 185

Registration Number: NCT00655135

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Malignancies

Interventions: Drug: alisertib

First Posted Date: 2008-04-03

Last Posted Date: 2019-03-15

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 59

Registration Number: NCT00651664

Locations: 🇪🇸
H. Clínico Universitario de Valencia, Valencia, Spain
🇪🇸
Ciutat Sanitaria Vall d'Hebron - Servicio de Oncologia, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy